BHVNHealthcare · BiotechnologyThe 17 Wall Street analysts covering Biohaven Ltd. hold a median 12-month price target of $20 — +67.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 32 of 100 as at 8 Oct 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Biohaven Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (79): Sales and profits are climbing, and climbing faster than before.
Issuance (17): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BHVN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +67.6% from it.
Of the 20 most recent actions, 2 moved their price target up and 2 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Sept 2026 | HC Wainwright & Co. | Reiterates | Neutral | $10 |
| 8 Sept 2026 | RBC Capital | Downgrade | Sector Perform | $23 → $19 |
| 12 Aug 2026 | Morgan Stanley | Maintains | Overweight | $18 → $19 |
| 12 Aug 2026 | Morgan Stanley | Maintains | Overweight | — |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | $22 → $23 |
| 11 Aug 2026 | RBC Capital | Maintains | Outperform | — |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | $12 → $11 |
| 29 June 2026 | B of A Securities | Downgrade | Underperform | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 13 May 2026 | Morgan Stanley | Maintains | Overweight | — |
| 5 May 2026 | RBC Capital | Maintains | Outperform | — |
| 2 Apr 2026 | Citigroup | Maintains | Buy | — |
| 11 Mar 2026 | TD Cowen | Maintains | Buy | — |
| 4 Mar 2026 | HC Wainwright & Co. | Maintains | Neutral | — |
| 3 Mar 2026 | RBC Capital | Maintains | Outperform | — |
| 21 Jan 2026 | RBC Capital | Upgrade | Outperform | — |
| 6 Jan 2026 | Morgan Stanley | Maintains | Overweight | — |
| 26 Dec 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 3 Dec 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 26 Nov 2025 | UBS | Downgrade | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BHVN appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 8 Oct 2026, Biohaven Ltd. returned −22.2% against +16.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 85% of US stocks
Cheaper than 1% of US stocks
Cheaper than 77% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 2% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biohaven Ltd. has a market value of $1.8B and an enterprise value of $1.9B.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$586.8M.
Diluted earnings per share, trailing twelve months: $−4.64.
Free cash flow in the twelve months to 30 June 2026: −$511.9M.
Trailing P/E: −1.8×; forward P/E: −6.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Biohaven Ltd. employs 274 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biohaven Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Biohaven Ltd. entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
Why it matters — The agreement expands Biohaven’s licensing and collaboration footprint in Asia.
Biohaven entered an exclusive licensing agreement granting Ono rights to develop and commercialize its MoDE pan-IgG degraders in Japan, South Korea, Taiwan, and ASEAN member states, led by BHV-1300. Biohaven will receive $80 million upfront, may receive another $20 million upon a milestone anticipated within a year, and is eligible for royalties of approximately 20% on Ono's net sales in the territory.
Why it matters — The agreement provides Biohaven with near-term payments and potential territory-based royalties for its IgG degrader programs.
Biohaven announced that Phase 1 findings from its ongoing BHV1530-101 study of BHV-1530, a first-in-class FGFR3-directed antibody-drug conjugate with a proprietary TopoIx payload, were selected for an oral presentation at the 38th EORTC-NCI-AACR Symposium (ENA 2026). The presentation will feature early clinical activity and a differentiated, tolerable safety profile.
Why it matters — An oral presentation slot at a leading international oncology symposium highlights external recognition of early clinical data for a key pipeline candidate, providing BHVN watchers insight into BHV-1530's development progress.
A law firm has notified investors of a pending investigation into Biohaven after the company's shares fell about 14.73% on September 10, 2026. The decline followed Biohaven's disclosure that the FDA placed a partial clinical hold on new-patient enrollment in its BHV-7000/opakalim epilepsy trials.
Why it matters — The FDA partial clinical hold on new-patient enrollment in a key epilepsy program and the resulting investigation could affect the outlook for one of Biohaven's major pipeline assets.
Regulators placed a partial hold on a clinical study for Biohaven's epilepsy drug candidate, opakalim. The news comes as Biohaven's stock is already declining, and a rival drugmaker stands to benefit from the setback.
Why it matters — A partial clinical hold on a key pipeline candidate like opakalim represents another setback for Biohaven and could affect the company's development timeline and competitive position.
The 17 Wall Street analysts covering Biohaven Ltd. have a median 12-month price target of $20, with estimates ranging from $10 to $42. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 17 analysts covering Biohaven Ltd., 12 rate it a Buy, 4 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Biohaven Ltd. 32 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 8 Oct 2026, Biohaven Ltd. ranks 32 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (79 of 100).
No one can know that. What the data says: the median 12-month target from 17 analysts implies +67.6% from the last close, and Ticker Nerd's factor model ranks Biohaven Ltd. 32 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biohaven Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHVN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $42 over the next 12 months.
Biohaven Ltd. returned -22.2% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology.
The most recent item we track (Benzinga, 8 Oct 2026): "Biohaven Expands Asian Licensing Footprint Through Strategic Ono Agreement". Biohaven Ltd. entered into a licensing and collaboration agreement with Ono Pharmaceutical Co., Ltd.
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies in immunology, obesity, neuroscience, and oncology. The company’s current portfolio includes drug candidates for neurological and neuropsychiatric disorders, epilepsy, pain, neuroinflammatory conditions, and rare diseases, alongside programs aimed at immune-mediated and cancer-related indications. Biohaven uses multiple proprietary development platforms, including approaches such as ion channel modulation, extracellular protein degradation, and antibody-drug conjugates, to build a diversified pipeline of investigational medicines. Headquartered in New Haven, Connecticut, Biohaven serves as a research-driven biopharmaceutical platform centered on advancing novel treatments across both common and underserved disease areas.
CEO Dr. Vladimir Coric M.D. · 274 employees · United States · https://www.biohaven.com
